8 terminated. 8 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Terminated 8 |
| Phase 2 | 1 | Terminated 1 |
Follow Coronavirus: new trials by email Literature Review of Coronavirus trials Research Report on Coronavirus
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| COVID-19: A Study to Evaluate Safety, Reactogenicity and Immunogenicity of the SARS-CoV-2 mRNA Vaccine CVnCoV in Adults With Co-morbidities CVnCoV Vaccine - Coronavirus, Covid19 | Phase 3 | Terminated | CureVac | 129 | 2021-04-22 | 2022-05-13 |
| Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19 Linagliptin 5 MG - COVID 19, Coronavirus | Phase 3 | Terminated | Rabin Medical Center | 64 | 2020-10-01 | 2021-06-02 |
| A Study to Assess Pulsed Inhaled Nitric Oxide vs Placebo in Subjects With Mild or Moderate COVID-19 INOpulse, Placebo - COVID-19, Coronavirus | Phase 3 | Terminated | Bellerophon Pulse Technologies | 191 | 2020-07-12 | 2023-02-21 |
| A Study to Evaluate Efficacy and Safety of PTC299 (Emvododstat) in Hospitalized Participants With Coronavirus (COVID-19) PTC299, SOC, Placebo - Pneumonia, COVID-19 | Phase 2 / Phase 3 | Terminated | PTC Therapeutics | 189 | 2020-07-09 | 2023-06-26 |
| Does Hydroxychloroquine Before & During Patient Exposure Protect Healthcare Workers From Coronavirus? Hydroxychloroquine, Placebo oral tablet - Pre-Exposure Prophylaxis, Coronavirus | Phase 3 | Terminated | Megan Landes | 13 | 2020-04-30 | 2021-04-29 |
| Will Hydroxychloroquine Impede or Prevent COVID-19 Hydroxychloroquine - Daily Dosing, Hydroxychloroquine - Weekly Dosing, Placebo oral tablet - COVID-19, Coronavirus | Phase 3 | Terminated | Henry Ford Health System | 624 | 2020-04-07 | 2022-06-21 |
| Hydroxychloroquine Versus Placebo in COVID-19 Patients at Risk for Severe Disease Hydroxychloroquine, Placebo - Coronavirus | Phase 3 | Terminated | University Hospital, Angers | 259 | 2020-04-01 | 2020-10-06 |
| Preemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP Canada) Hydroxychloroquine, Placebo oral tablet - Corona Virus Infection, SARS-CoV Infection | Phase 3 | Terminated | McGill University Health Centre/Research Institute of the McGill University Health Centre | 70 | 2020-03-25 | 2024-10-15 |
Coronavirus Infections (8) · COVID-19 (7) · Severe Acute Respiratory Syndrome (3) · Pneumonia (2) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 2 (1) · Endocrine System Diseases (1) · Glucose Metabolism Disorders (1) · Metabolic Diseases (1) · Respiratory Tract Diseases (1)
Coronaviridae Infections (8) · Infections (8) · Nidovirales Infections (8) · RNA Virus Infections (8) · Virus Diseases (8) · Lung Diseases (7) · Pneumonia, Viral (7) · Respiratory Tract Infections (7) · Respiratory Tract Diseases (6) · Pneumonia (5) · Nutritional and Metabolic Diseases (1)
Hydroxychloroquine (3) · CVnCoV COVID-19 vaccine (1) · Linagliptin (1) · emvododstat (1)
Bellerophon Pulse Technologies (1) · CureVac (1) · Henry Ford Health System (1) · McGill University Health Centre/Research Institute of the McGill University Health Centre (1) · Megan Landes (1) · PTC Therapeutics (1) · Rabin Medical Center (1) · University Hospital, Angers (1)
United States (4) · Belgium (2) · Canada (2) · France (2) · Australia (1) · Brazil (1) · Colombia (1) · Israel (1) · Mexico (1) · Monaco (1) · Poland (1) · Portugal (1) · South Africa (1) · Spain (1)
Ashika Ahmed, MD (1) · Dee Dee Wang, MD (1) · Kevin Kain, MD (1) · Megan Landes, MD (1) · Quintus Ngumah, OD, PhD (1) · Todd C Lee, MD MPH FIDSA (1) · William W O'Neill, MD (1)